Atomo Diagnostics (AT1) Q4 2025 earnings summary

Executive summary

• Strategic U.S. partnership for FebriDx via Pascal device, with a major supply agreement and CLIA waiver study nearing completion.

• Strong growth in Australian HIV self-test business, supported by federal funding and public health initiatives, with sales up 143% year-on-year to $1.4m.

• Board renewal and capital restructuring to align with strategic goals, including new directors with diagnostics expertise.

• Advanced development and launch of new diagnostic products, including the Active Syphilis test and Florey accessory device.

• Cost reduction and balance sheet strengthening position the company for future growth.

Financial highlights

• Quarterly revenue reported at $1.07 million; full-year revenue and grant income reached ~$4.2 million, up 2.7% year-over-year.

• Cash receipts for the quarter were $1.52 million, including $485k from a CRC-P grant.

• Operating costs for the quarter were $1.6 million; full-year costs down to $6.9 million from $7.1 million in FY24.

• Ended the quarter debt-free with $3.2 million cash on hand.

• Share placement and SPP raised a net total of $2.6 million, with an additional $926k post-year-end.

Outlook and guidance

• Anticipated sizable demand for FebriDx Pascal in the U.S. market following CLIA waiver approval and expansion to new customers.

• Plans to expand HIV self-test distribution beyond Australia, targeting Europe, Central/South America, and Southeast Asia.

• Continued focus on developing and commercializing new diagnostic products, including syphilis and other pipeline tests.

• Commercialization of Active Syphilis test variants and Florey device adoption planned.

• Focus on improving margins through manufacturing efficiencies and operational improvements.